Suppr超能文献

危重新生儿动脉低血压治疗的评估

Assessment of therapy for arterial hypotension in critically ill preterm infants.

作者信息

Ruelas-Orozco G, Vargas-Origel A

机构信息

Hospital de Gineco-Pediatría 48, Centro Médico Nacional, Instituto Mexicano del Seguro Social, Léon, Gto.

出版信息

Am J Perinatol. 2000;17(2):95-9. doi: 10.1055/s-2000-9265.

Abstract

The aim of this paper is to assess the efficacy of albumin and dopamine compared with albumin and dobutamine in treating hypotension in preterm newborn infants (PNI). A randomized, open-label, prospective, cross-over study, was designed on 66 PNI whose weights were between 1,000 to 1,500 g, and persistent hypotension, defined as a mean arterial pressure (MAP) of < 30 mmHg. Infants were randomly allocated to two groups and received a 5% albumin infusion at a dosage of 20 mL/kg, in 30 min. Thereafter, one group received dopamine and the other dobutamine at doses of 5 microg/kg/min. If there was not an increase in MAP values > 30 mmHg, the infusions were increased every 20 min by 2.5 microg/kg/min, up to a maximum of 10 microg/kg/min. Treatment failure was considered when there was no pressure response within 2 hr after the infusion started; then patients were changed to the other catecholamine. Statistical analysis was done with student's t-test, x2, and Fisher's exact probability test. There were no differences between groups in initial features. Overall, MAP was normalized with dopamine in 29 of 33 infants and with dobutamine in 25 of 33 infants (p > 0.05). The initial dosage of 5 microg/kg/min, was adequate in 22 infants treated with dopamine and in 13 treated with dobutamine (p < 0.05). The change from dopamine to dobutamine was successful in three out of four patients, while changing from dobutamine to dopamine was adequate in seven out of eight patients. Dopamine is recognized as the drug of choice to treat hypotension in PNI. Since our results showed only small differences in responses, it is proposed that dobutamine is also as efficacious and useful as dopamine.

摘要

本文旨在评估白蛋白联合多巴胺与白蛋白联合多巴酚丁胺治疗早产儿低血压(PNI)的疗效。对66例体重在1000至1500克之间且持续低血压(定义为平均动脉压(MAP)<30 mmHg)的早产儿进行了一项随机、开放标签、前瞻性、交叉研究。婴儿被随机分为两组,在30分钟内接受20 mL/kg剂量的5%白蛋白输注。此后,一组接受剂量为5微克/千克/分钟的多巴胺,另一组接受多巴酚丁胺。如果MAP值升高未超过30 mmHg,则每20分钟将输注剂量增加2.5微克/千克/分钟,最高可达10微克/千克/分钟。输注开始后2小时内无压力反应则视为治疗失败;然后将患者换用另一种儿茶酚胺。采用学生t检验、x²检验和Fisher精确概率检验进行统计分析。两组的初始特征无差异。总体而言,33例婴儿中29例使用多巴胺使MAP恢复正常,33例婴儿中25例使用多巴酚丁胺使MAP恢复正常(p>0.05)。5微克/千克/分钟的初始剂量对22例接受多巴胺治疗的婴儿和13例接受多巴酚丁胺治疗的婴儿足够(p<0.05)。4例患者中有3例从多巴胺换用多巴酚丁胺成功,8例患者中有7例从多巴酚丁胺换用多巴胺合适。多巴胺被认为是治疗早产儿低血压的首选药物。由于我们的结果显示反应仅存在微小差异,因此建议多巴酚丁胺与多巴胺一样有效且有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验